Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 7 for:    "Hepatitis B" | "Sargramostim"

Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients (NPGV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03332329
Recruitment Status : Active, not recruiting
First Posted : November 6, 2017
Last Update Posted : November 6, 2017
Sponsor:
Information provided by (Responsible Party):
Qin Ning, Tongji Hospital

Brief Summary:
The aim of the prospective study is to determine whether combination/ sequential therapy with Entecavir, Peginterferon alfa-2b and immunomodulators Granulocyte Macrophage Colony Stimulating Factor (GMCSF)+vaccine could induce HBsAg loss in chronic hepatitis B patients with maintained Hepatitis B Virus (HBV) DNA suppression on long-term nucleoside or nucleotide analogue (NA).

Condition or disease Intervention/treatment Phase
Chronic Hepatitis b Drug: Entecavir Drug: Granulocyte Macrophage Colony Stimulating Factor Drug: Y peginterferon alfa-2b Drug: HBV vaccine Phase 4

Detailed Description:
Patents who were treated with NA at least one year and achieved HBV DNA suppression are enrolled in this study, they will receive Entecavir (ETV) for 60 weeks, HBV vaccine (60ug/month, every four weeks) for 24 weeks, GMCSF (75 μg/day, first 5 days each month, subcutaneous) from baseline to week 16 and from week 60 to week 84, and Y peginterferon alfa-2b (180 μg/week, subcutaneous) from week 16 to week 108.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Combination Therapy With Entecavir, Peginterferon Alfa-2b and Immunomodulators in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients
Actual Study Start Date : December 1, 2015
Estimated Primary Completion Date : December 31, 2018
Estimated Study Completion Date : December 31, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Sequential combination arm
Drug: Entecavir for 60 weeks Drug: HBV vaccine (60ug/month, every four weeks) for 24 weeks Drug: Granulocyte Macrophage Colony Stimulating Factor (75 μg/day, first 5 days each month, subcutaneous) from baseline to week 16 and from week 60 to week 84 Drug: Y peginterferon alfa-2b (180 μg/week, subcutaneous) from week 16 to week 108
Drug: Entecavir
Entecavir is used for 96 weeks
Other Name: ETV

Drug: Granulocyte Macrophage Colony Stimulating Factor
Granulocyte-macrophage colony stimulating factor is used intermittently from baseline to week 16 and from 60 to week 84
Other Name: GMCSF

Drug: Y peginterferon alfa-2b
Y peginterferon alfa-2b is used for 96 weeks
Other Name: peginterferon a-2b

Drug: HBV vaccine
60ug HBV vaccine is used every four week for 24 weeks
Other Name: vaccine




Primary Outcome Measures :
  1. HBsAg loss rate [ Time Frame: at week 108 ]
    Percentages of patients who achieve HBsAg loss at the end of treatment


Secondary Outcome Measures :
  1. HBsAg level [ Time Frame: at week 60 ]
    Dynamic change in HBsAg level from baseline to the end of treatment

  2. HBsAg level [ Time Frame: at week 108 ]
    Dynamic change in HBsAg level from baseline to the end of treatment

  3. decline in HBsAg level [ Time Frame: at week 60 ]
    Decline in HBsAg level from baseline to the end of treatment

  4. decline in HBsAg level [ Time Frame: at week 108 ]
    Decline in HBsAg level from baseline to the end of treatment

  5. HBsAb appearance rate [ Time Frame: at week 108 ]
    Percentages of HBsAb appearance at the end of treatment

  6. HBsAb seroconversion rate [ Time Frame: at week 108 ]
    Percentages of HBsAb seroconversion at the end of treatment

  7. HBeAg loss rate [ Time Frame: at week 108 ]
    Percentages of HBeAg loss in the HBeAg-positive patients at the end of treatment

  8. HBeAg seroconversion rate [ Time Frame: at week 108 ]
    Percentages of HBeAg seroconversion in the HBeAb-negative patients at the end of treatment

  9. Rate of HBV DNA level <1000 copies/mL [ Time Frame: at week 108 ]
    Percentages of HBV DNA level <1000 copies/mL at the end of treatment

  10. Rate of alanine aminotransferase (ALT) normalisation [ Time Frame: at week 108 ]
    Percentages of ALT normalisation at the end of treatment

  11. Sustained HBsAg loss rate [ Time Frame: at week 156 ]
    Percentages of sustained HBsAg loss at the end of follow-up

  12. The rate of progression to cirrhosis [ Time Frame: at week 156 ]
    The rate of progression to cirrhosis at the end of follow-up

  13. The incidence rate of hepatocarcinoma [ Time Frame: at week 156 ]
    The incidence rate of hepatocarcinoma at the end of follow-up



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female patients from 18 to 65 years of age;
  2. HBsAg positive, entecavir and or adefovir dipivoxil are used at least 1 year including patients with nucleotides or nucleoside resistance history;
  3. Before nucleotides or nucleosides treatment, ALT > 2 upper limit of normal value (ULN), HBV DNA >10000 copies/ml, HBsAg positive;
  4. Serum HBV DNA < 1000 copies/ml;
  5. 2000 IU/ml ≤HBsAg≤6000 IU/ml;
  6. HBsAg positive;
  7. Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of test drug;
  8. Absence of cirrhosis confirmed by ultrasonic test;
  9. Agree to participate in the study and sign the patient informed consent.

Exclusion Criteria:

  1. Patients who had NAs resistance and HBV DNA > 1000 copies/ml, or treatment of drugs with interferon longer than 6 months;
  2. Other antiviral, anti-neoplastic or immunomodulatory treatment (including supra physiologic doses of steroids and radiation) 6 months prior to the first dose of randomized treatment (except for 7 days of acyclovir for herpetic lesions more than 1 month prior to first administration of randomized treatment). Patients who are expected to need systemic antiviral therapy other than that provided by the study at any time during their participation are also excluded;
  3. Women with ongoing pregnancy or breast-feeding;
  4. Co-infection with active hepatitis A, hepatitis C, hepatitis D(Those hospitals which have the ability to do the test will do) and/or human immunodeficiency virus (HIV);
  5. ALT >10 ULN;
  6. Evidence of decompensated liver disease (Child-Pugh score > 5). Child-Pugh > 5 means, if one of the following 5 conditions are met, the patient has to be excluded:
  7. one of the following 5 conditions are met, the patient has to be excluded:
  8. Serum albumin < 3.5 g/L;
  9. Prothrombin time > 3 seconds prolonged;
  10. Serum bilirubin > 34 µ mol/L;
  11. History of encephalopathy;
  12. History of variceal bleeding;
  13. Ascites;
  14. History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures, thalassemia);
  15. Signs or symptoms of hepatocellular carcinoma, patients with a value of alpha-fetoprotein > 100 ng/mL are excluded, unless stability (less than 10% increase) has been documented over at least the previous 3 months. Patients with values < 20 ng/mL but > 100 ng/mL may be enrolled, if hepatic neoplasia has been excluded by liver imaging;
  16. Neutrophil count < 1500 cells/mm3 or platelet count <90,000 cells/mm3 at screening;
  17. Hemoglobin < 11.5 g/dL for females and <12.5 g/dL for men;
  18. Serum creatinine level > 1.5 ULN in screening period.
  19. Phosphorus < 0.65 mmol/L;
  20. antinuclear antibody (ANA) > 1:100;
  21. History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease;
  22. History of a severe seizure disorder or current anticonvulsant use;
  23. History of immunologically mediated disease, (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis etc.);
  24. History of chronic pulmonary disease associated with functional limitation;
  25. Diseases that interferon and Nucleotides or nucleosides are not suitable.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03332329


Sponsors and Collaborators
Qin Ning
Investigators
Layout table for investigator information
Principal Investigator: Qin Ning Tongji Hospital

Layout table for additonal information
Responsible Party: Qin Ning, Prof, Tongji Hospital
ClinicalTrials.gov Identifier: NCT03332329     History of Changes
Other Study ID Numbers: NPGV study
First Posted: November 6, 2017    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Qin Ning, Tongji Hospital:
HBsAg
PegIFN
ETV
Chronic Hepatitis B (CHB)
HBV
GMCSF
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis B
Hepatitis B, Chronic
Sargramostim
Hepatitis A
Hepatitis
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Entecavir
Peginterferon alfa-2b
Interferon-alpha
Vaccines
Immunologic Factors
Physiological Effects of Drugs
Antiviral Agents
Anti-Infective Agents